World-Leading Therapeutic Technologies at Your Disposal
An Introduction to Our Technology
Phage display is based on genetic engineering of coat proteins of filamentous bacteriophages. Unlike hybridoma technology, phage display allows the selection of antibodies against an almost unlimited array of biological and non-biological targets, including self-antigens, while completely bypassing the use of animals. A prime example of a phage-selected monoclonal antibody is Adalimumab (Humira), an anti-TNF monoclonal selected by Cambridge Antibody Technology and developed and marketed by Abbott. Used for the treatment of moderate to severe rheumatoid arthritis, Humira was the first fully human monoclonal to obtain regulatory approval.
Key to selection success is the ability to perform robust and appropriate selection screens using peptides, whole proteins or cells expressing the antigens of interest. IONTAS has extensive experience in the preparation of correctly folded native target protein to facilitate the screening process and in the development of appropriate assays to validate lead selection. Antibodies can be further enhanced by affinity maturation to improve binding affinities to the desired antigen or to introduce further properties such as cross species reactivity.